## AMENDMENTS TO THE CLAIMS

1. (Original) A compound represented by the formula:



wherein m is 1 or 2;

$R^1$ is a halogen atom or an optionally halogenated $C_{1-2}$ alkyl group;

one of $R^2$ and $R^3$ is a hydrogen atom and the other is a group represented by the formula:



or



wherein n is 3 or 4; $R^4$ is a $C_{1-4}$ alkyl group substituted by 1 or 2 hydroxy groups, or a salt thereof.

**2. (Original)** A compound as claimed in claim 1, wherein $R^1$ is fluoro or trifluoromethyl, or a salt thereof.

**3. (Original)** A compound as claimed in claim 1, wherein $R^2$ is a group represented by the formula:



and $R^3$ is a hydrogen atom; or

$R^2$ is a hydrogen atom and $R^3$ is a group represented by the formula:



or a salt thereof.

**4. (Original)** A compound as claimed in claim 1, wherein $R^2$ is a group represented by the formula:



and $R^3$ is a hydrogen atom, or a salt thereof.

**5. (Original)** A compound as claimed in claim 1, wherein m is 1;

$R^1$ is 4-trifluoromethyl;

$R^2$ is a group represented by the formula:



and $R^3$ is a hydrogen atom, or a salt thereof.

**6. (Currently Amended)** A compound as claimed in claim 1, which is

~~1-(4-{4-[(2-{(E)-2-[4-(trifluoromethyl)phenyl]ethenyl}-1,3-oxazol-4-yl)methoxy]phenyl}butyl)-1H-1,2,3-triazole;~~

1-(3-{3-[(2-{(E)-2-[4-(trifluoromethyl)phenyl]ethenyl}-1,3-oxazol-4-yl)methoxy]phenyl}propyl)-1H-1,2,3-triazole, or 3-(1-{4-[4-({2-[(E)-2-(2,4-difluorophenyl)ethenyl]-1,3-oxazol-4-yl}methoxy)phenyl]butyl}-1H-imidazol-2-yl)-1,2-propanediol, or a salt thereof.

**7. (Original)** A method for producing a compound as claimed in claim 1 or a salt thereof comprising reacting a compound represented by the formula:




wherein X is a leaving group; the other symbols have the same meanings as defined in claim 1, or a salt thereof, with a compound represented by the formula:




wherein the symbols have the same meanings as defined in claim 1, or a salt thereof.

**8. (Original)** A pro-drug of a compound as claimed in claim 1 or a salt thereof.

**9. (Original)** A pharmaceutical composition containing a compound as claimed in claim 1 or a salt thereof or a pro-drug thereof.

**10. (Original)** A pharmaceutical composition as claimed in claim 9, which is a tyrosine kinase inhibitor.

**11. (Original)** A pharmaceutical composition as claimed in claim 9, which is an agent for preventing or treating cancer.

**12. (Original)** A pharmaceutical composition as claimed in claim 11, wherein the cancer is breast cancer or prostate cancer.

**13. (Original)** A pharmaceutical composition as claimed in claim 11, wherein the cancer is lung cancer.

**14. (Original)** A pharmaceutical composition which combines a compound as claimed in claim 1 or a salt thereof or a pro-drug thereof and other anti-cancer agents.

**15. (Original)** A pharmaceutical composition which combines a compound as claimed in claim 1 or a salt thereof or a pro-drug thereof and hormonal therapeutic agents.

**16. (Original)** The pharmaceutical composition as claimed in claim 15, wherein the hormonal therapeutic agent is a LH-RH modulator.

**17. (Original)** The pharmaceutical composition as claimed in claim 16, wherein the LH-RH modulator is LH-RH antagonist.

**18. (Original)** The pharmaceutical composition as claimed in claim 17, wherein the LH-RH antagonist is leuprorelin or a salt thereof.

**19. (Original)** A method for inhibiting tyrosine-kinase which comprises administering an effective amount of a compound as claimed in claim 1 or a salt thereof or a pro-drug thereof to mammals.

**20. (Original)** A method for preventing or treating cancer which comprises administering an effective amount of a compound as claimed in claim 1 or a salt thereof or a pro-drug thereof to mammals.

**21. (Original)** A method for preventing or treating cancer which comprises combining (1) administering an effective amount of a compound as claimed in claim 1 or a salt thereof or a pro-drug thereof to mammals and (2) 1 to 3 selected from the group consisting (i) administering an effective amount of other anti-cancer agents to mammals, (ii) administering an effective amount of hormonal therapeutic agents to mammals and (iii) non-drug therapy.

**22. (Original)** The method as claimed in claim 21 wherein non-drug therapy is surgery, hypertensive chemotherapy, genetherapy, thermotherapy, cryotherapy, laser cauterization and/or radiotherapy.

**23. (Original)** A method for preventing or treating cancer which comprises administering in combination of an effective amount of a compound as claimed in claim 1 or a salt thereof or a pro-drug thereof and an effective amount of other anti-cancer agents to mammals.

**24. (Original)** A method for preventing or treating cancer which comprises administering in combination of an effective amount of a compound as claimed in claim 1 or a salt thereof or a pro-drug thereof and an effective amount of hormonal therapeutic agents to mammals.

**25. (Original)** The method as claimed in claim 24, wherein the hormonal therapeutic agent is a LH-RH modulator.

**26. (Original)** The method as claimed in claim 25, wherein the LH-RH modulator is LH-RH antagonist.

**27. (Original)** The method as claimed in claim 26, wherein the LH-RH antagonist is leuprorelin or a salt thereof.

**28. (Original)** A method for preventing or treating cancer which comprises administering an effective amount of a compound as claimed in claim 1 or a salt thereof or a pro-drug thereof to mammals before surgery, hypertensive chemotherapy, genetherapy, thermotherapy, cryotherapy, laser cauterization and/or radiotherapy.

**29. (Original)** A method for preventing or treating cancer which comprises administering an effective amount of a compound as claimed in claim 1 or a salt thereof or a pro-drug thereof to mammals after surgery, hypertensive chemotherapy, genetherapy, thermotherapy, cryotherapy, laser cauterization and/or radiotherapy.

**30. (Original)** A method for preventing or treating cancer which comprises administering in combination of an effective amount of a compound as claimed in claim 1 or a salt thereof or a pro-drug thereof and an effective amount of other anti-cancer agents to mammals before surgery, hypertensive chemotherapy, genetherapy, thermotherapy, cryotherapy, laser cauterization and/or radiotherapy.

**31. (Original)** A method for preventing or treating cancer which comprises administering in combination of an effective amount of a compound as claimed in claim 1 or a salt thereof or a pro-drug thereof and an effective amount of other anti-cancer agents to mammals before surgery, hypertensive chemotherapy, genetherapy, thermotherapy, cryotherapy, laser cauterization and/or radiotherapy.

**32. (Original)** The method as claimed in claim 31, wherein the hormonal therapeutic agent is a LH-RH modulator.

**33. (Original)** The method as claimed in claim 32, wherein the LH-RH modulator is LH-RH antagonist.

**34. (Original)** The method as claimed in claim 33, wherein the LH-RH antagonist is leuprorelin or a salt thereof.

**35. (Original)** A method for preventing or treating cancer which comprises administering in combination of an effective amount of a compound as claimed in claim 1 or a salt thereof or a pro-drug thereof and an effective amount of other anti-cancer agents to mammals after surgery, hypertensive chemotherapy, genetherapy, thermotherapy, cryotherapy, laser cauterization and/or radiotherapy.

**36. (Original)** A method for preventing or treating cancer which comprises administering in combination of an effective amount of a compound as claimed in claim 1 or a salt thereof or a pro-drug thereof and an effective amount of other anti-cancer agents to mammals after surgery, hypertensive chemotherapy, genetherapy, thermotherapy, cryotherapy, laser cauterization and/or radiotherapy.

**37. (Original)** The method as claimed in claim 36, wherein the hormonal therapeutic agent is a LH-RH modulator.

**38. (Original)** The method as claimed in claim 37, wherein the LH-RH modulator is LH-RH antagonist.

**39. (Original)** The method as claimed in claim 38, wherein the LH-RH antagonist is leuprorelin or a salt thereof.

**40. (Cancelled)**

**41. (Cancelled)**

**42. (Original)** A compound represented by the formula:




wherein $R^{1a}$ is fluoro or trifluoromethyl, $X^1$ is a leaving group, and n is 3 or 4, or a salt thereof.

**43. (Original)** A compound as claimed in claim 42, wherein $X^1$ is a halogen atom.

**44. (Cancelled)**